Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Bone BiologicsBBLG -27.60%32 EV-to-EBITDA is 1.11 as of Aug. 12, 2026. GuruFocus rates BBLG with a GF Score™ of 32/100. Among 398 Biotechnology companies, Bone Biologics ranks better than 80.4% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Bone Biologics's enterprise value is $-3.34 Mil.
Bone Biologics's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 was $-3.00 Mil. Therefore, Bone Biologics's EV-to-EBITDA for today is 1.11.
The historical rank and industry rank for Bone Biologics's EV-to-EBITDA or its related term are showing as below:
BBLG'
s EV-to-EBITDA Range Over the Past 10 Years
Min: 0 Med: 0 Max: 1.13
Current: 1.11
During the past 12 years, the highest EV-to-EBITDA of Bone Biologics was 1.13. The lowest was 0.00. And the median was 0.00.
BBLG's EV-to-EBITDA is ranked better than 80.4% of 398
companies
in the Biotechnology industry
Industry Median: 13.395
vs BBLG: 1.11
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
Bone Biologics (NAS:BBLG) EV-to-EBITDA Explanation
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Bone Biologics's PE Ratio (TTM) for today is calculated as:
Bone Biologics's share price for today is $0.658.
Bone Biologics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-2.511.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for Bone Biologics's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Bone Biologics's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Bone Biologics EV-to-EBITDA vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Bone Biologics's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Bone Biologics's EV-to-EBITDA falls into.
Bone Biologics's current Enterprise Value is $-3.34 Mil.
Bone Biologics's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-3.00 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Bone Biologics (BBLG) has a EV-to-EBITDA of 1.11 as of Aug. 12, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Bone Biologics. According to the industry distribution chart, Bone Biologics ranks #78 out of 398 companies in the Biotechnology industry, placing it in the top 19.6%.
Is Bone Biologics' EV-to-EBITDA too high?
Bone Biologics' current EV-to-EBITDA is 1.11. The Biotechnology industry median EV-to-EBITDA is 13.40. Bone Biologics' value of 1.11 is 91.7% below this industry median. Based on the distribution chart, Bone Biologics ranks #78 out of 398 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Bone Biologics has a GF Score™ of 32/100, reflecting its overall financial health beyond just this single metric.
How does Bone Biologics' EV-to-EBITDA compare to CDT and CLDI?
According to the Biotechnology industry distribution chart, Bone Biologics ranks #78 out of 398 companies for EV-to-EBITDA. This places Bone Biologics in the top 20% of its industry — outperforming the majority of peers. The industry median EV-to-EBITDA is 13.40. Bone Biologics' value of 1.11 is 91.7% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Biotechnology company?
The median EV-to-EBITDA among Biotechnology companies is 13.40, based on 398 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Bone Biologics's current EV-to-EBITDA of 1.11 is 91.7% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Bone Biologics. For the Biotechnology industry, the median EV-to-EBITDA is 13.40 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Bone Biologics's current EV-to-EBITDA is 1.11. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bone Biologics stock overvalued right now?
Bone Biologics (BBLG) has a current EV-to-EBITDA of 1.11. The current EV-to-EBITDA is 1.11 and 91.7% below the Biotechnology industry median of 13.40. Bone Biologics' overall GF Score™ is 32/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Bone Biologics (BBLG), the current EV-to-EBITDA is 1.11 as of Aug. 12, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Bone Biologics Corp a medical device company that is currently focused on bone regeneration in spinal fusion using the recombinant human protein known as NELL-1. NELL-1 in combination with DBM, demineralized bone matrix, is an osteopromotive recombinant protein that provides target specific control over bone regeneration. It is a clinical-stage entity. The production and marketing of its products and ongoing research and development activities are subject to extensive regulation by numerous governmental authorities in the United States.
32GF Score
Get the complete analysis for BBLG
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BBLG has been successfully added to your 
